Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., Hebert, V., Houivet, E., et al. (2017) First-Line Rituximab Combined with Short-Term Prednisone versus Prednisone Alone for the Treatment of Pemphigus (Ritux 3): A Prospective, Multicenter, Parallel-Group, Open-Label Randomized Trial. The Lancet, 389, 2031-2040.
https://doi.org/10.1016/S0140-6736(17)30070-3

has been cited by the following article:

• TITLE: Rituximab Therapy for Persistent, Severe and Extensive Idiopathic Bullous Pemphigoid

  AUTHORS: Shaima Al-Bader, Kamel El-Reshaid

  KEYWORDS: Bullous Pemphigoid, Rituximab, Treatment, BP Autoantibodies, Bullous Pemphigoid Disease Area Index

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.13 No.1, March 29, 2023

  ABSTRACT: Background: Idiopathic Bullous Pemphigoid (IBP) is a rare blistering autoimmune disease. Its morbidity and mortality have remained high owing to complications of extensive skin involvement as well as its conventional steroid therapy. We reviewed the medical literature and found indicators of an autoimmune etiology for its pathogenesis triggering genetically predisposed patients. Objective: to evaluate, prospectively, the role of Rituximab (R) therapy in its persistent, severe and extensive form. Patients and methods: A total of 12 patients, with disease duration of 6 ± 1 months, were treated with yearly R infusions (1 g followed by 1 g 2 weeks later). Results: Significant clinical improvement was achieved as documented by decrease in total score of Bullous Pemphigoid Disease Area Index from 60 ± 3 to 6 ± 2 that persisted for 26 ± 11 months of follow up. Moreover, IBP autoantibodies (anti-BP 180 and anti-320 IgG) levels fell from to 91 ± 3 and 81 ± 2 to 8 ± 2 and 9 ± 2, respectively. Conclusions: R is a safe and effective treatment for severe IBP and such response further confirms its autoimmune pathogenesis.